Improvement of Neurodegenerative Disease after Use of Vemurafenib in Refractory BRAF V600E-Mutated Langerhans Cell Histiocytosis: A Case Report
Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder characterized by heterogenous lesions infiltrated with CD1a+/CD207+ cells. Although LCH has a relatively good prognosis, the prognosis for patients with LCH refractory to standard chemotherapy is poor. Neurodegenerative LCH (ND-LCH)...
Main Authors: | Young Kwon Koh, Su Hyun Yoon, Sung Han Kang, Hyery Kim, Ho Joon Im, Pyeong Hwa Kim, Ah Young Jung, Kyung-Nam Koh |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Pediatric Hematology-Oncology
2022-10-01
|
Series: | Clinical Pediatric Hematology-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.15264/cpho.2022.29.2.97 |
Similar Items
-
Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review
by: Qingqing Li
Published: (2023-12-01) -
Adult Langerhans Cell Histiocytosis and the Skeleton
by: Danae Georgakopoulou, et al.
Published: (2022-02-01) -
Multisystemic langerhans-cell histiocytosis with dominant lesions of the lung parenchyma
by: Javorac Jovan, et al.
Published: (2020-01-01) -
Aggressive unifocal bone Langerhans cell histiocytosis with soft tissue extension both responsive to radiotherapy: a case report
by: Wilmar Ghuijs, et al.
Published: (2022-08-01) -
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease
by: Váradi Z, et al.
Published: (2017-01-01)